Geneva, Switzerland-based Ares-Serono SA says that for 1996 net incometotaled $53.5 million, 82% higher than the previous year. Operating income amounted to $95.9 million compared with $66.1 million in 1995, or 11.9% (9.7%) as a percentage of sales. Net sales increased 18% to $805 million; unaudited sales were announced earlier (Marketletter January 27).
The group's board is recommending to shareholders that they approve the creation of authorized capital of the company for use for new R&D ventures. The objective of these would be the acquisition of new and innovative technologies with a focus on the USA, in order to fill A-R's development pipeline for the 21st century. R&D spending in 1996 increased to $159.2 million ($146.1 million in 1995).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze